Brentuximab Vedotin
Peripheral T-Cell Lymphoma, Not Otherwise Specified
Explore 128 assets in Peripheral T-Cell Lymphoma, Not Otherwise Specified →Floatz Rating
B63/100
Confidence
Indicative
Sponsor
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Modality
antibody_drug_conjugate
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07624838CT.gov Real-life Experience of Brentuximab Vedotin Plus CHP as First-line Treatment of CD30+ Peripheral T-cell Lymphomas in Spain | — | Recruiting | — | — | — |
NCT05006664CT.gov Brentuximab Vedotin in Combination With CHEP in Patient With PTCL | — | Unknown | — | — | — |
NCT04569032CT.gov A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression | — | Completed | — | — | — |
NCT04254107CT.gov A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | — | Terminated | — | — | — |
NCT04795869CT.gov Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma | — | Withdrawn | — | — | — |
NCT04213209CT.gov Special Drug Use Surveillance for Brentuximab Vedotin Intravenous Infusion "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Pediatric Hodgkin Lymphoma" | — | Completed | — | — | — |
NCT03947255CT.gov A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma | — | Terminated | — | — | — |
NCT03719105CT.gov Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma | — | Recruiting | — | — | — |
NCT03302728CT.gov Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma | — | Completed | — | — | — |
NCT03496779CT.gov Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine | — | Completed | — | — | — |
Show 5 more trialsShow fewer
NCT03113500CT.gov Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT01841021CT.gov Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30 | — | Terminated | — | — | — |
NCT07258680CT.gov BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell Lymphomas | — | Enrolling By Invitation | — | — | — |
NCT01805037CT.gov Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas | — | Terminated | — | — | — |
NCT01716806CT.gov A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Peripheral T-Cell Lymphoma, Not Otherwise Specified
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Brentuximab Vedotin (this asset) | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | P3 | B · 63 |
| Adriamycin | BeBetter Med Inc | P4 | BBB |
| Pralatrexate | Peking University People's Hospital | P4 | BBB |
| Prednisone | Tarapeutics Science Inc. | P4 | BBB |
| Cyclophosphamide | Tarapeutics Science Inc. | P4 | BBB |
| (+)-Vincristine | BeBetter Med Inc | P4 | BBB |
| Rivoceranib | Ruijin Hospital | P4 | BBB |
| Romidepsin | University of Virginia | P3 | BBB |
| Tucidinostat | Ruijin Hospital | P4 | BB |
+42 more in the Peripheral T-Cell Lymphoma, Not Otherwise Specified cohort
Other indications for Brentuximab Vedotin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| T-Cell Non-Hodgkin Lymphoma | — | P4 | BBB · 73 |
| Anaplastic Large Cell Lymphoma | — | P3 | BBB · 72 |
| Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | — | P3 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Brentuximab Vedotin in Peripheral T-Cell Lymphoma, Not Otherwise Specified. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/brentuximab-vedotin-peripheral-t-cell-lymphoma-not-otherwise-specified
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →